PMI 001 as stand-alone therapy in patients with rheumatoid arthritis: first of three US-based phase III trials

Trial Profile

PMI 001 as stand-alone therapy in patients with rheumatoid arthritis: first of three US-based phase III trials

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2010

At a glance

  • Drugs Tripterygium wilfordii Hook F (Primary)
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 09 Nov 2010 Status changed from recruiting to active, no longer recruiting, based on a Phytomedics media release.
    • 12 Sep 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top